NCT03338712撤回不适用
Micro-RNA Expression Profiles in Localised Prostate Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Recurrence free survival
研究概览
简要总结
Recurrence free survival The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 35 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •35 Years to 80 Years
- •Patients with clinically localised high risk prostate cancer
排除标准
- 未提供
结局指标
主要结局
Recurrence free survival
时间窗: Up to 120 months. From date of inclusion until date of death from any cause
The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association.
次要结局
- Cancer specific survival(Up to 120 months. From date of inclusion until date of death from any cause)
研究者
相似试验
已完成
2 期
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate CancerProstate CancerNCT01558427University Hospital, Ghent62
进行中（未招募）
不适用
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® TestingProstate CancerNCT04404894Myriad Genetic Laboratories, Inc.500
招募中
3 期
Longitudinal Follow-up in Women With Endometrial Hyperplasia Without AtypiaFemaleNCT05292573Chang Gung Memorial Hospital1,000
终止
不适用
Micro-RNA Expression Profiles in High Risk Prostate CancerRadical ProstatectomyProstate CancerNCT01220427Wuerzburg University Hospital300
招募中
不适用
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical TrialsProstate AdenocarcinomaProstate Cancer MetastaticCastration-resistant Prostate CancerProstate CancerNCT06141993Duke University120